Alex R Chang1, Edgar R Miller2, Cheryl A Anderson3, Stephen P Juraschek4, Melissa Moser5, Karen White6, Bobbie Henry5, Caitlin Krekel5, Susan Oh5, Jeanne Charleston2, Lawrence J Appel2. 1. Geisinger Health System, Division of Nephrology, Danville, PA. Electronic address: achang@geisinger.edu. 2. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD; Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD. 3. Department of Family and Preventive Medicine, University of California, San Diego, CA. 4. Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD. 5. Institute for Clinical and Translational Research, Johns Hopkins University, Baltimore, MD. 6. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD.
Abstract
BACKGROUND: Little is known about the effects of phosphorus additives on patients with kidney disease. STUDY DESIGN: Randomized, double-blind, crossover trial. SETTING & PARTICIPANTS: 31 adults with early stages of presumed chronic kidney disease (estimated glomerular filtration rate ≥ 45mL/min/1.73m2; urine albumin-creatinine ratio sex-specific cutoff points: men ≥ 17mg/g, women ≥ 25mg/g). INTERVENTION: Higher versus lower phosphorus intake for 3 weeks. Higher phosphorus intake was achieved by the addition of commercially available diet beverages and breakfast bars to diet. OUTCOMES: Change in 24-hour urine albumin excretion and plasma fibroblast growth factor 23 level. MEASUREMENTS: Two 24-hour urine collections and a single fasting blood draw at the end of each period. RESULTS:Mean baseline values for phosphorus intake, 24-hour urine phosphorus excretion, and estimated glomerular filtration rate were 1,113±549 (SD) mg/d, 688±300mg/d, and 74.6±22.0mL/min/1.73m2. Median urine albumin excretion of 82.7 (IQR, 39.6-174.1) mg/d. Although phosphorus intake from study products increased by 993mg/d (P<0.001) during the higher compared to lower phosphorus additive period, background phosphorus intake decreased by 151mg/d (P=0.004). Higher phosphorus additive consumption increased 24-hour urine phosphorus excretion by 505 (95% CI, 381 to 629) mg/d (P<0.001), but did not significantly increase albuminuria (higher vs lower: 14.3%; 95% CI, -2.5% to 34.0%; P=0.1) or fibroblast growth factor 23 level (higher vs lower: 3.4%; 95% CI, -5.9% to 13.6%; P=0.4). LIMITATIONS: Small sample size, short duration of intervention, changes in background diet during the intervention. CONCLUSIONS: A 3-week consumption of higher phosphorus food additives did not significantly increase albuminuria. Further studies are needed to confirm these results.
RCT Entities:
BACKGROUND: Little is known about the effects of phosphorus additives on patients with kidney disease. STUDY DESIGN: Randomized, double-blind, crossover trial. SETTING & PARTICIPANTS: 31 adults with early stages of presumed chronic kidney disease (estimated glomerular filtration rate ≥ 45mL/min/1.73m2; urine albumin-creatinine ratio sex-specific cutoff points: men ≥ 17mg/g, women ≥ 25mg/g). INTERVENTION: Higher versus lower phosphorus intake for 3 weeks. Higher phosphorus intake was achieved by the addition of commercially available diet beverages and breakfast bars to diet. OUTCOMES: Change in 24-hour urine albumin excretion and plasma fibroblast growth factor 23 level. MEASUREMENTS: Two 24-hour urine collections and a single fasting blood draw at the end of each period. RESULTS: Mean baseline values for phosphorus intake, 24-hour urine phosphorus excretion, and estimated glomerular filtration rate were 1,113±549 (SD) mg/d, 688±300mg/d, and 74.6±22.0mL/min/1.73m2. Median urine albumin excretion of 82.7 (IQR, 39.6-174.1) mg/d. Although phosphorus intake from study products increased by 993mg/d (P<0.001) during the higher compared to lower phosphorus additive period, background phosphorus intake decreased by 151mg/d (P=0.004). Higher phosphorus additive consumption increased 24-hour urine phosphorus excretion by 505 (95% CI, 381 to 629) mg/d (P<0.001), but did not significantly increase albuminuria (higher vs lower: 14.3%; 95% CI, -2.5% to 34.0%; P=0.1) or fibroblast growth factor 23 level (higher vs lower: 3.4%; 95% CI, -5.9% to 13.6%; P=0.4). LIMITATIONS: Small sample size, short duration of intervention, changes in background diet during the intervention. CONCLUSIONS: A 3-week consumption of higher phosphorus food additives did not significantly increase albuminuria. Further studies are needed to confirm these results.
Authors: Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee Journal: Clin J Am Soc Nephrol Date: 2010-10-28 Impact factor: 8.237
Authors: Alex R Chang; Mariana Lazo; Lawrence J Appel; Orlando M Gutiérrez; Morgan E Grams Journal: Am J Clin Nutr Date: 2013-11-13 Impact factor: 7.045
Authors: Maartje C J Slagman; Femke Waanders; Marc H Hemmelder; Arend-Jan Woittiez; Wilbert M T Janssen; Hiddo J Lambers Heerspink; Gerjan Navis; Gozewijn D Laverman Journal: BMJ Date: 2011-07-26
Authors: Jeewoo Kim; Juyeon Lee; Kyoung-Nam Kim; Kook-Hwan Oh; Curie Ahn; Jongkoo Lee; Daehee Kang; Sue K Park Journal: Int J Environ Res Public Health Date: 2018-05-24 Impact factor: 3.390
Authors: Valerie K Sullivan; Lawrence J Appel; Jesse C Seegmiller; Scott T McClure; Casey M Rebholz Journal: J Nutr Date: 2021-10-01 Impact factor: 4.687